115 related articles for article (PubMed ID: 37906601)
1. Fisetin-Loaded Nanostructured Lipid Carriers: Formulation and Evaluations against Advanced and Metastatic Melanoma.
Kumar H; Chand P; Pachal S; Mallick S; Jain R; Madhunapantula SV; Jain V
Mol Pharm; 2023 Dec; 20(12):6035-6055. PubMed ID: 37906601
[TBL] [Abstract][Full Text] [Related]
2. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder(s).
Garg NK; Sharma G; Singh B; Nirbhavane P; Tyagi RK; Shukla R; Katare OP
Int J Pharm; 2017 Jan; 517(1-2):413-431. PubMed ID: 27956192
[TBL] [Abstract][Full Text] [Related]
3. Dermatokinetic assessment of luliconazole-loaded nanostructured lipid carriers (NLCs) for topical delivery: QbD-driven design, optimization, and in vitro and ex vivo evaluations.
Mahmood A; Rapalli VK; Gorantla S; Waghule T; Singhvi G
Drug Deliv Transl Res; 2022 May; 12(5):1118-1135. PubMed ID: 33895936
[TBL] [Abstract][Full Text] [Related]
4. Formulation of Stattic as STAT3 inhibitor in nanostructured lipid carriers (NLCs) enhances efficacy of doxorubicin in melanoma cancer cells.
Mohammadian J; Mahmoudi S; Pourmohammad P; Pirouzpanah M; Salehnia F; Maroufi NF; Samadi N; Sabzichi M
Naunyn Schmiedebergs Arch Pharmacol; 2020 Dec; 393(12):2315-2323. PubMed ID: 32653978
[TBL] [Abstract][Full Text] [Related]
5. Formulation of intranasal surface engineered nanostructured lipid carriers of rotigotine: Full factorial design optimization, in vitro characterization, and pharmacokinetic evaluation.
Zafar A; Awad Alsaidan O; Alruwaili NK; Sarim Imam S; Yasir M; Saad Alharbi K; Singh L; Muqtader Ahmed M
Int J Pharm; 2022 Nov; 627():122232. PubMed ID: 36155794
[TBL] [Abstract][Full Text] [Related]
6. Design and dermatokinetic evaluation of Apremilast loaded nanostructured lipid carriers embedded gel for topical delivery: A potential approach for improved permeation and prolong skin deposition.
Rapalli VK; Sharma S; Roy A; Singhvi G
Colloids Surf B Biointerfaces; 2021 Oct; 206():111945. PubMed ID: 34216849
[TBL] [Abstract][Full Text] [Related]
7. Development, in vitro and in vivo evaluation of miltefosine loaded nanostructured lipid carriers for the treatment of Cutaneous Leishmaniasis.
Khan AS; Ud Din F; Ali Z; Bibi M; Zahid F; Zeb A; Mujeeb-Ur-Rehman ; Khan GM
Int J Pharm; 2021 Jan; 593():120109. PubMed ID: 33253802
[TBL] [Abstract][Full Text] [Related]
8. Design and evaluation of cabazitaxel loaded NLCs against breast cancer cell lines.
Chand P; Kumar H; Badduri N; Gupta NV; Bettada VG; Madhunapantula SV; Kesharwani SS; Dey S; Jain V
Colloids Surf B Biointerfaces; 2021 Mar; 199():111535. PubMed ID: 33360926
[TBL] [Abstract][Full Text] [Related]
9. Nanostructured lipid carrier mediates effective delivery of methotrexate to induce apoptosis of rheumatoid arthritis via NF-κB and FOXO1.
Garg NK; Tyagi RK; Singh B; Sharma G; Nirbhavane P; Kushwah V; Jain S; Katare OP
Int J Pharm; 2016 Feb; 499(1-2):301-320. PubMed ID: 26768725
[TBL] [Abstract][Full Text] [Related]
10. Preparation, Pharmacokinetics, and Antitumor Potential of Miltefosine-Loaded Nanostructured Lipid Carriers.
Yu G; Ali Z; Sajjad Khan A; Ullah K; Jamshaid H; Zeb A; Imran M; Sarwar S; Choi HG; Ud Din F
Int J Nanomedicine; 2021; 16():3255-3273. PubMed ID: 34012260
[TBL] [Abstract][Full Text] [Related]
11. Development of ritonavir-loaded nanostructured lipid carriers employing quality by design (QbD) as a tool: characterizations, permeability, and bioavailability studies.
Gurumukhi VC; Bari SB
Drug Deliv Transl Res; 2022 Jul; 12(7):1753-1773. PubMed ID: 34671949
[TBL] [Abstract][Full Text] [Related]
12. Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: preformulation screening studies and statistical hybrid-design for optimization of variables.
Rathod VR; Shah DA; Dave RH
Drug Dev Ind Pharm; 2020 Mar; 46(3):443-455. PubMed ID: 32037896
[TBL] [Abstract][Full Text] [Related]
13. Novel Strategies against Cancer: Dexibuprofen-Loaded Nanostructured Lipid Carriers.
Thiruchenthooran V; Świtalska M; Bonilla L; Espina M; García ML; Wietrzyk J; Sánchez-López E; Gliszczyńska A
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232614
[TBL] [Abstract][Full Text] [Related]
14. Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides.
Yang G; Wu F; Chen M; Jin J; Wang R; Yuan Y
Int J Nanomedicine; 2019; 14():2267-2280. PubMed ID: 31015758
[TBL] [Abstract][Full Text] [Related]
15. Formulation optimization, in vitro and in vivo evaluation of agomelatine-loaded nanostructured lipid carriers for augmented antidepressant effects.
Gul M; Shah FA; Sahar NU; Malik I; Din FU; Khan SA; Aman W; Choi HI; Lim CW; Noh HY; Noh JS; Zeb A; Kim JK
Colloids Surf B Biointerfaces; 2022 Aug; 216():112537. PubMed ID: 35561634
[TBL] [Abstract][Full Text] [Related]
16. Formulation, characterization, and evaluation of in vitro skin permeation and in vivo pharmacodynamics of surface-charged tripterine-loaded nanostructured lipid carriers.
Chen Y; Zhou L; Yuan L; Zhang ZH; Liu X; Wu Q
Int J Nanomedicine; 2012; 7():3023-32. PubMed ID: 22787398
[TBL] [Abstract][Full Text] [Related]
17. Sucrose ester stabilized solid lipid nanoparticles and nanostructured lipid carriers. I. Effect of formulation variables on the physicochemical properties, drug release and stability of clotrimazole-loaded nanoparticles.
Das S; Ng WK; Tan RB
Nanotechnology; 2014 Mar; 25(10):105101. PubMed ID: 24531790
[TBL] [Abstract][Full Text] [Related]
18. Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy.
Alam T; Pandit J; Vohora D; Aqil M; Ali A; Sultana Y
Expert Opin Drug Deliv; 2015 Feb; 12(2):181-94. PubMed ID: 25164097
[TBL] [Abstract][Full Text] [Related]
19. Development of Oral Lipid Based Nano-formulation of Dapagliflozin: Optimization, in vitro Characterization and ex vivo Intestinal Permeation Study.
Zafar A
J Oleo Sci; 2020; 69(11):1389-1401. PubMed ID: 33132278
[TBL] [Abstract][Full Text] [Related]
20. Nanostructured Lipid Carriers for Oral Bioavailability Enhancement of Exemestane: Formulation Design, In Vitro, Ex Vivo, and In Vivo Studies.
Singh A; Neupane YR; Mangla B; Kohli K
J Pharm Sci; 2019 Oct; 108(10):3382-3395. PubMed ID: 31201904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
